Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Sashi Nadanaciva"'
Autor:
Grant Generaux, Vinal V. Lakhani, Yuching Yang, Sashi Nadanaciva, Luping Qiu, Keith Riccardi, Li Di, Brett A. Howell, Scott Q. Siler, Paul B. Watkins, Hugh A. Barton, Michael D. Aleo, Lisl K. M. Shoda
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Abstract Many compounds that appear promising in preclinical species, fail in human clinical trials due to safety concerns. The FDA has strongly encouraged the application of modeling in drug development to improve product safety. This study illustra
Externí odkaz:
https://doaj.org/article/828b1d4c830842609ef4d255b6b2b62b
Autor:
Li Li, Sashi Nadanaciva, Zdenek Berger, Wei Shen, Katrina Paumier, Joel Schwartz, Kewa Mou, Paula Loos, Anthony J Milici, John Dunlop, Warren D Hirst
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e85815 (2013)
Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is α-synuclein (α-syn). Human genetic studies have shown that mutations (A53T, A30P,
Externí odkaz:
https://doaj.org/article/d66a11a109554bf685a5e666188f4884
Autor:
Bosung Ku, Jonathan S. Dordick, Kyeong-Nam Yu, Payal Rana, Moo-Yeal Lee, Alexander Roth, Sashi Nadanaciva, Dong Woo Lee, Yvonne Will
Publikováno v:
Archives of Toxicology. 92:1295-1310
Human liver contains various oxidative and conjugative enzymes that can convert nontoxic parent compounds to toxic metabolites or, conversely, toxic parent compounds to nontoxic metabolites. Unlike primary hepatocytes, which contain myriad drug-metab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa90a734816880c5d234ea1a6c139a01
https://doi.org/10.1007/s00204-017-2126-3
https://doi.org/10.1007/s00204-017-2126-3
Autor:
Jane Liang White, Seiji Niho, Tony Mok, R. Linke, Adam Pluzanski, Sashi Nadanaciva, Kazuhiko Nakagawa, Xiangdong Zhou, Ying Cheng, Jesus Corral, Ki Hyeong Lee, Tao Wang, Rafael Rosell, Rickard Sandin, Eric Sbar, Fumito Tsuji, Yi-Long Wu, Maria Rita Migliorino
Publikováno v:
The Lancet Oncology. 18:1454-1466
Summary Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7b7ad3eac8d3f0ab930716a25cc8d7a
https://doi.org/10.1016/s1470-2045(17)30608-3
https://doi.org/10.1016/s1470-2045(17)30608-3
Autor:
Stephen T. Sonis, Sashi Nadanaciva, Mario E. Lacouture, Edward B. Garon, Tao Wang, Dong Wan Kim, Nagdeep Giri, Eric Sbar, Joe O'Connell, Aminah Jatoi, Dorothy M. K. Keefe, Diana Gernhardt, Jim P. Doherty, Byoung Chul Cho
Publikováno v:
Lung Cancer. 106:76-82
Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ab8a4545c6f376edf642728f19bed55
https://doi.org/10.1016/j.lungcan.2017.01.021
https://doi.org/10.1016/j.lungcan.2017.01.021
Autor:
Keith Riccardi, Hugh A. Barton, Paul B. Watkins, Lisl K.M. Shoda, Li Di, Grant T. Generaux, Yuching Yang, Brett A. Howell, Michael D. Aleo, Sashi Nadanaciva, Scott Q. Siler, Vinal V. Lakhani, Luping Qiu
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Many compounds that appear promising in preclinical species, fail in human clinical trials due to safety concerns. The FDA has strongly encouraged the application of modeling in drug development to improve product safety. This study illustrates how D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc3454f90654ea81ae25f045c065f6d9
http://europepmc.org/articles/PMC6785660
http://europepmc.org/articles/PMC6785660
Autor:
Diana Gernhardt, Dorothy M. K. Keefe, Eric Sbar, Jim P. Doherty, Mario E. Lacouture, Nagdeep Giri, Aminah Jatoi, Tao Wang, Joe O'Connell, Bilal Piperdi, Edward B. Garon, Stephen T. Sonis, Sashi Nadanaciva
Publikováno v:
Annals of Oncology. 27:1712-1718
Background ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epiderma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93710680a02c0c2371796c4ec7c64d33
https://doi.org/10.1093/annonc/mdw227
https://doi.org/10.1093/annonc/mdw227
Autor:
Johannes Ettl, C Huang Bartlett, Yaroslav Shparyk, Ravindranath Patel, S.-B. Kim, Tamás Pintér, Xin-Yun Huang, DJ Slamon, Sophia Randolph, J.P. Crown, Richard S. Finn, Anu Thummala, Sashi Nadanaciva
Publikováno v:
Cancer Research. 76:P4-13
Background Palbociclib (P) is an oral CDK4/6 inhibitor. In PALOMA-1/TRIO-18, a randomized phase 2 trial, addition of P to letrozole (L) significantly prolonged progression-free survival (PFS) (20 mo with P+L vs 10 mo with L alone; HR = 0.488, P=0.000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ddfa1a2982f214114dd65f6f7baea5a
https://doi.org/10.1158/1538-7445.sabcs15-p4-13-02
https://doi.org/10.1158/1538-7445.sabcs15-p4-13-02
Autor:
Yvonne Will, Michael D. Aleo, Huijun Wang, Sashi Nadanaciva, Donald B. Stedman, Christopher J. Strock
Publikováno v:
Toxicology and Applied Pharmacology. 272:272-280
To reduce costly late-stage compound attrition, there has been an increased focus on assessing compounds in in vitro assays that predict attributes of human safety liabilities, before preclinical in vivo studies are done. Relevant questions when choo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e086b38de90f89c0e4d74f8238d9c096
https://doi.org/10.1016/j.taap.2013.06.019
https://doi.org/10.1016/j.taap.2013.06.019
Publikováno v:
Toxicology in Vitro. 27:1789-1797
Drug-induced mitochondrial dysfunction is known to contribute to late stage compound attrition. Recently, assays that identify mitochondrial dysfunction have been developed but many require expensive reagents, specialized equipment, or specialized ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f34cca69bc88d40ce787189bcddaba
https://doi.org/10.1016/j.tiv.2013.05.007
https://doi.org/10.1016/j.tiv.2013.05.007